Verrica Pharmaceuticals Inc. - Common Stock - Nakit Akışı (NASDAQ:VRCA) | MetaTrader

Tam grafiği aç Full chart

Financials

Genel Bakış Tablolar İstatistikler

Çeyreklik Yıllık

İşletme faaliyetlerinden elde edilen nakit -30.21 M-27.58 M-18.65 M-38.58 M-60.93 M-17.63 M -14.11 M Yatırım faaliyetlerinden elde edilen nakit -3.58 M-998 K54.04 M-362 K-19 K0 0 Finansman faaliyetlerinden elde edilen nakit 35.23 M33.65 M-16.87 M74.21 M37.73 M1.45 M 5.38 M Serbest nakit akışı -30.21 M-27.58 M-18.65 M-38.58 M-60.93 M-17.63 M -14.11 M

Haberler

Verrica Pharmaceuticals Inc. (VRCA) Q1 2026 Earnings Call Transcript

Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

Neurocrine Biosciences (NBIX) Beats Q1 Earnings and Revenue Estimates

Verrica Pharmaceuticals Inc. (VRCA) Q4 2025 Earnings Call Transcript

Verrica Pharmaceuticals hisseleri, YCANTH’in Japonya’da piyasaya sürülmesiyle yükseldi

Verrica Pharmaceuticals stock rises after partner launches YCANTH in Japan

Verrica’s partner launches molluscum treatment in Japan

Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why

New Strong Buy Stocks for February 2nd

How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11%

Verrica Pharmaceuticals hisseleri TD Cowen’ın Al tavsiyesini yinelemesiyle yükseldi